Background
Three main imaging techniques are commonly used to identify cardiac transthyretin (ATTR) amyloidosis: echocardiography, MRI and DPD scintigraphy. Each one provides specific diagnostic and prognostic informations but also has its specific limitations. We sought to evaluate a multimodality imaging strategy to diagnose cardiac amyloidosis in ATTR.
Methods
Seventy seven consecutive patients with multimodality imaging evaluation (echocardiography, 1.5T MRI and 99mTc-DPD scintigraphy) to diagnose cardiac amyloidosis were identified from the database of the French National Reference Center for Amyloidosis. Patients with pacemaker or severe renal failure did not undergo cardiac MRI and were analyzed on the basis of the echocardiography and scintigraphy (n=17). Three groups were compared: patients with positive agreement to diagnose cardiac ATTR (PA-ATTR group), patients with positive agreement to exclude cardiac ATTR (PA-normal) and patients with negative agreement (NA).
Results
The mean age was 52 years ; 59% were male. Transthyretin mutations were Val30Met in 67%, other in 21%, and 12% had acquired ATTR from previous domino liver transplantation; 30 patients had a positive echocardiography, 37 positive MRI and 36 positive DPD scintigraphy. Positive imaging agreement was encountered in 50/77 patients (65%: 30 PA-ATTR and 20 PA-normal 
Conclusions
In transthyretin amyloidosis, the agreement between echocardiography, cardiac MRI and DPD scintigraphy to diagnose cardiac amyloidosis was observed in 65% of patients. Patients without agreement between these three techniques had distinct patterns of cardiac involvement: sole positivity of the MRI was encountered in patients in the early stages of ATTR; patients with acquired ATTR due to domino liver transplantation often had negative DPD scintigraphy. 
